Lumexa Imaging Holdings, Inc. (LMRI)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Wall Street Analysts Think Lumexa (LMRI) Could Surge 44.08%: Read This Before Placing a Bet
The mean of analysts' price targets for Lumexa (LMRI) points to a 44.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Lumexa (LMRI) Could Rally 73.25%: Here's is How to Trade
The consensus price target hints at a 73.3% upside potential for Lumexa (LMRI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Lumexa Imaging Holdings, Inc. (LMRI) Q1 2026 Earnings Call Transcript
Lumexa Imaging Holdings, Inc. (LMRI) Q1 2026 Earnings Call Transcript
Lumexa Imaging Q1 Earnings Call Highlights
Lumexa Imaging NASDAQ: LMRI reported first-quarter results that management said were in line with expectations, as growth in advanced imaging modalities helped offset seasonal volume pressure and weather-related disruptions.
Lumexa Imaging Holdings, Inc. (LMRI) Q4 2025 Earnings Call Transcript
Lumexa Imaging Holdings, Inc. (LMRI) Q4 2025 Earnings Call Transcript
Lumexa Imaging: Clearer Growth Path Ahead
Lumexa Imaging remains a Buy, with Q4 2025 results clarifying the medium-term growth and margin trajectory. Advanced imaging volumes and mix are rising, driving superior unit economics and margin expansion; FastScan rollout is a key throughput catalyst. De novo center openings reached a record, with rapid breakeven timelines supporting compounding organic growth and future margin upside.
Lumexa Imaging: Resilient Demand With Compounding Scale Moat
Lumexa Imaging (LMRI) earns a Buy rating due to resilient outpatient imaging demand, demographic tailwinds, and a scalable business model. LMRI benefits from a secular shift toward outpatient imaging, driven by lower costs, insurer incentives, and consumer preference for convenience. The joint venture model with hospitals locks in referral flows, enhances reimbursement rates, and creates high switching costs, reinforcing LMRI's moat.
